FDA grants full approval to Moderna’s COVID-19 vaccine


Shares of Moderna Inc. MRNA, +2.71% gained 3.4% in trading on Monday after the company said it received full approval from the Food and Drug Administration for its COVID-19 vaccine, which is now called Spikevax. The FDA has granted full approval to one other COVID-19 shot: BioNTech SE BNTX, +3.21% and Pfizer Inc.’s PFE, -3.33% Comirnaty. The Spikevax approval is for adults, though the vaccine still has emergency authorization for use in teens and as a booster dose. Moderna’s stock is down 4.5% over the past year, while the broader S&P 500 SPX, +0.65% is up 17.0%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleThe Moneyist: ‘She took his queen-size bed for herself’: My sister mooched off my father while pretending to be his caregiver. Then he died a painful death.
Next articleModerna’s COVID-19 vaccine receives full FDA approval


Please enter your comment!
Please enter your name here